BGI Genomics Co (SZSE:300676) Net Income From Continuing Operations : ¥65 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. BGI Genomics Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥12 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥65 Mil.

BGI Genomics Co Net Income From Continuing Operations Historical Data

The historical data trend for BGI Genomics Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Net Income From Continuing Operations Chart

BGI Genomics Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

278.52

2,102.05

1,477.70

809.29

93.68

BGI Genomics Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															41.20	10.72	18.23	23.54	12.15

BGI Genomics Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥65 Mil.

BGI Genomics Co (SZSE:300676) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083

Website

http://www.bgi.com

BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.

Executives

Wang Jian	Director
Liu Na	Executives
Sun Ying Jun	Director
Yin Ye	Directors, executives
Du Yu Tao	Directors, executives
Li Song Gang	Supervisors
Hu Yu Jie	Supervisors
Xu Qian	Secretary Dong
Li Zhi Ping	Executives
Chen Yi Qing	Executives
Li Wen Qi	Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines